Gene therapy aims to turn back the clock on aging

NCT ID NCT07285629

Recruiting now Disease control Sponsor: Minicircle Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase study is testing a gene therapy that delivers two proteins, klotho and follistatin, via a simple injection. The goal is to see if it is safe and can improve cognition and overall health in healthy adults aged 50 to 80. Thirty volunteers will receive the therapy and be monitored for side effects and changes in protein levels.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: klotho and follistatin gene therapy (nonviral plasmid injection)
What this could lead to: If successful, this could point toward a way to slow aging or improve cognitive function in older adults.
What could go wrong: This is a very early, small pilot study in only 30 healthy people. It is not yet tested for effectiveness, and side effects are unknown. Results may not apply to the general population.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY ADULTS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEALTHY ADULTS

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

Apeiron Center
RECRUITING

Austin, Texas, 78701, United States

Contact Email: •••••@•••••
Global Alliance of Regenerative Medicine (GARM) Clinic
NOT_YET_RECRUITING

Roatán, Bay Islands, Honduras

More trials for these conditions

Other studies related to the condition(s) this trial covers.